Navigation Links
CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
Date:2/13/2008

ATLANTA, Feb. 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the Roth Capital Partners 20th Annual OC Growth Stock Conference, February 19, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, Calif.

D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Tuesday, February 19 at 8:30 a.m., Pacific Time.

CryoLife's live presentation may be accessed through its Web site, http://www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for its CryoValve(R) SG pulmonary human heart valves, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Chief Financial Officer Fleishman Hillard

and Chief Operating Officer Phone: 770-419-3355

Phone: 404-739-0150


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
2. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
3. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
4. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
5. CryoLife Announces Record Preservation Services and Product Revenues for 2007
6. CryoLife to Present at OneMedPlace Finance Forum
7. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
8. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
9. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
10. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
11. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):